# Pharmaceuticals
Latest news and articles about Pharmaceuticals
Total: 16 articles found
ChiNext Plunges as Chinese Growth Sectors Retreat Amid Regional Volatility
China’s ChiNext index dropped nearly 4% on Tuesday as a sell-off in metals and tech-linked sectors offset gains in pharmaceuticals and robotics. Shrinking trading volumes and regional market instability in East Asia have combined to dampen investor sentiment in the world's second-largest economy.
AbbVie’s $11 Billion Gambit: Securing the Future of Immunology Beyond the Humira Cliff
AbbVie has entered an agreement to acquire Apogee Therapeutics for $10.9 billion to bolster its immunology portfolio. The deal focuses on zumilokibart, a next-generation treatment for inflammatory diseases that offers significantly less frequent dosing than current market leaders.
China’s Biotech Ambitions: Shanghai Launches Elite Training to Bridge the Clinical Trial Talent Gap
Shanghai has launched a high-level training initiative to equip clinical trial Principal Investigators with the international leadership skills necessary to lead global research. The project aims to harmonize Chinese clinical standards with international benchmarks, supporting the global expansion of China's innovative drug industry.
Protecting the Lab: China Solidifies Drug Data Protection in Historic Regulatory Overhaul
China has implemented a major revision to its drug administration laws, introducing a tiered system that protects clinical trial data for up to six years. This reform aims to incentivize high-end pharmaceutical innovation and align China's intellectual property regime with global standards.
Governance Shadow Over China’s CRO Giant: Tigermed Founders Targeted by Regulators
The founders of Tigermed, China's leading clinical CRO, are under investigation by the CSRC for disclosure violations regarding past shareholding changes. Despite a massive 1 billion RMB buyback plan to reassure markets, the company faces significant headwinds including a 70% drop in quarterly net profit.
From Gold Mine to Glut: The Darkest Hour for China’s HPV Vaccine Giants
China's leading HPV vaccine manufacturers, Wantai and Zhifei, have reported record financial losses as the market shifts from scarcity to a massive oversupply. A combination of high vaccination rates among wealthy demographics and aggressive government price-cutting has collapsed profit margins, forcing a difficult strategic pivot.
Eli Lilly Bets $7 Billion on the ‘Holy Grail’ of Cancer Therapy to Diversify Beyond Weight Loss
Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion to gain access to its revolutionary in-vivo CAR-T technology. This strategic move aims to diversify Lilly's portfolio beyond its successful weight-loss business and establish a leading position in the high-growth oncology market.
China’s Tech-Heavy ChiNext Retreats After Testing Decade-Highs Amid Profit-Taking
China's ChiNext index hit its highest level since the 2015 bubble before reversing sharply to close down over 1%. Despite a massive 2.42 trillion yuan turnover, the market saw widespread declines, though pharmaceutical and AI-leasing stocks bucked the downward trend.
China’s Pharma Roadmap: Beijing Unveils Strategic Pivot to High-Value Innovation and AI Integration
China's MIIT has announced the framework for the 15th Five-Year Plan for the pharmaceutical industry, focusing on accelerating drug innovation, lowering prices through AI integration, and addressing the needs of elderly and rare-disease patients. The policy aims to balance industrial growth with public affordability while positioning Chinese biotech as a competitive global force.
Neural Rewiring: Shanghai Biotech Secures Global First with Dual US-China Approval for Epilepsy Cell Therapy
Shanghai's Yuesai Biotechnology has become the first company globally to receive IND approval from both the US FDA and China's CDE for an iPSC-derived cell therapy targeting refractory epilepsy, marking a major breakthrough in regenerative medicine.
The 100% Bluff: Why Washington’s Radical Drug Tariff May Never Be Collected
The U.S. government’s announcement of a 100% tariff on imported drugs is essentially a tactical negotiation tool rather than a fiscal reality. Through a series of 'Most Favored Nation' deals and manufacturing incentives, the administration is using the threat of high tariffs to force global drugmakers into domestic investment and lower pricing.
A Bitter Pill: Trump’s 100% Drug Tariffs and the Future of Chinese Biotech
President Trump has signed an executive order under Section 232 to impose 100% tariffs on imported patent drugs and APIs, aimed at forcing price concessions and manufacturing onshoring. While Chinese biotech firms face new challenges, many are already pivoting toward U.S.-based production to mitigate these trade risks.